- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Eugene Science Inc. (OTCBB: EUSI), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ™) plant sterols, today announced it has retained Early Bird, Inc. (EBI) to market the Company's existing and newly expanded CZ™ plant sterol product lines throughout Japan.
EBI has contracted with Nihon Pharmaceutical Co., Ltd. to produce and distribute a CZ™ plant sterol enhanced cosmetic product line including skin cream, toothpaste, shampoos and pet goods -- initial launch is slated for first quarter, 2008. Based in Tokyo, Japan, Nihon generates approximately $1.6 billion in annual sales, was founded in 1921 and has about 560 employees. Nihon, through its subsidiaries, will also distribute CZ™ enhanced food products including pre-cooked rice, cooking oil, capsules, tablets, seaweed, dairy products and ice cream.
EBI expects to develop numerous production and distribution agreements with leading Japanese food, beverage and cosmetic manufacturers and distributors for the expanding Eugene Science CZ™ product lines.
The National Institutes of Health reports an estimated 80 percent of Americans currently have some form of periodontal, or gum, disease. Separately, research indicates that topically applied, plant sterols have chemical properties that are ideally suited for treating and preventing periodontal disease -- rendering sterols the preferred, natural additive for toothpaste for humans and animals alike.
Until now, the active ingredients in conventional plant sterols were too large at the molecular level to be effectively absorbed by gum tissue for use in toothpaste, or by human skin for use in moisturizing anti-aging creams, to deliver their healing benefits. Eugene Science's unique, patented nano-technology process for its CZ™ sterols, however, renders sterols into water dispersible, nano-sized particles that can permeate gum tissue and skin dramatically more effectively than conventional sterols to deliver powerful health benefits.
"Japan is the world's most sophisticated marketplace for nutraceutical food, beverage and cosmetic products as consumers are highly aware of nutraceutical benefits," said Seung Kwon Noh, Chief Executive Officer, Eugene Science. "Europe, North America and the rest of Asia look to and track new product introduction in Japan, providing Eugene Science both strategic advantage as well as strong near term revenue upside. Early Bird is off to a strong start with its Nihon agreement and we are confident this success will accelerate throughout 2008 and beyond."
To be added to Eugene Science's investor lists, please contact Zachary Bryant at or at 818-382-9718.
About Eugene Science Inc.
Based in Seoul, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ™, is a patented, nanoscience-based, water-dispersible functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy. Please visit www.eugene21.com.
Forward-Looking Statements: This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical or cosmetic industry; dependence on key personnel; actions of third parties; the market for cosmetic or nutraceutical products containing Eugene Science's CZ™ ingredient; and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
For more information, please click here
Investor Relations International
Senior Vice President and Account Group Manager
Company Contact for CZ™ Sales and Distribution
U.S. Headquarters (Los Angeles)
E: Email Contact
Early Bird Inc.
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
NRL reveals novel uniform coating process of p-ALD April 21st, 2016
New ORNL method could unleash solar power potential March 16th, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEI’s QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Region’s Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016